Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer
Brief Summary: This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is human epidermal growth factor receptor 2 (HER2)-positive and has spread to the lymph nodes or high-risk and has not spread to the lymph nodes. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without trastuzumab in treating breast cancer.


Options:
A: Arm Label: Conventional radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conventional radiotherapy | Arm Label: Tomotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Tomotherapy | Intervention Type: RADIATION; Name: Conventional radiotherapy; Assigned to Arm(s): Conventional radiotherapy | Intervention Type: RADIATION; Name: Tomotherapy; Assigned to Arm(s): Tomotherapy
B: Arm Label: Hypofractionated whole breast radiation; Type: EXPERIMENTAL; Interventions: Radiation: Hypofractionated whole breast radiation schedule | Arm Label: Conventional whole breast radiation; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conventional whole breast radiation schedule | Intervention Type: RADIATION; Name: Conventional whole breast radiation schedule; Assigned to Arm(s): Conventional whole breast radiation | Intervention Type: RADIATION; Name: Hypofractionated whole breast radiation schedule; Assigned to Arm(s): Hypofractionated whole breast radiation
C: Arm Label: Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate | Arm Label: Arm II (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Arm Label: Arm III (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Intervention Type: DRUG; Name: Aromatase Inhibition Therapy; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Tamoxifen Citrate; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: BIOLOGICAL; Name: Trastuzumab; Assigned to Arm(s): Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen)
D: Arm Label: Arm 1: adriamycin + cyclophosphamide then taxol; Type: ACTIVE_COMPARATOR; Interventions: Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Arm Label: Arm 2: adriamycin + cyclophosphamide then taxol + herceptin; Type: EXPERIMENTAL; Interventions: Biological: herceptin, Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Intervention Type: BIOLOGICAL; Name: herceptin; Assigned to Arm(s): Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: adriamycin; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: taxol; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin

Answer: C